Source: Annual Congress 2005 - Treatment options for moderate and severe asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. M. Beeh, H. Fox, P. Freeman, S. Hedgecock, C. Reisner (Wiesbaden, Germany; Horsham, United Kingdom; East Hanover, United States Of America). Omalizumab significantly improves quality of life in patients with severe persistent allergic asthma: a pooled analysis. Eur Respir J 2005; 26: Suppl. 49, 424

Member's Comments

No comment yet.

Related content which might interest you: Omalizumab significantly improves FEV1 in patients with severe persistent allergic asthma: a pooled analysis Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Omalizumab improves asthma-specific quality of life in patients with severe allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001 Improvement of control and quality of life in severe allergic asthmatics patients treated with omalizumab Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008 Dupilumab improves asthma control and quality of life in children with uncontrolled persistent asthma Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches Year: 2021 Adding omalizumab to high-dose ICS and LABA significantly improves quality of life in patients with severe persistent allergic asthma Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006 Effectiveness of omalizumab in improving quality of life in patients with ‘steroid-resistant‘ asthma and severe allergic rhinitis Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2012 Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study Source: International Congress 2017 – Monitoring asthma control Year: 2017 Analysis of causes and quality of patients‘ treatment with often severe asthma exacerbations Source: Eur Respir J 2007; 30: Suppl. 51, 72s Year: 2007 Improvements in asthma control and quality of life with omalizumab in allergic (IgE-mediated) asthma patients Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 Omalizumab in severe asthma: real life study Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Dupilumab improves patient-reported outcomes in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Omalizumab improves lung function in severe persistent allergic (IgE-mediated) asthma patients: Pooled data from 5 UK centres Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey Source: Eur Respir J 2013; 42: 1224-1233 Year: 2013 The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma Source: Eur Respir J 2002; 20: 1088-1094 Year: 2002 Efficacy of Omalizumab in adult and pediatric severe allergic asthma according to presence of multiple allergic comorbidities: evidence from the STELLAIR study. Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Patients with asthma and comorbid allergic rhinitis: Is optimal quality of life achievable in real life? Source: Annual Congress 2011 - Asthma: risk factors and comorbidities Year: 2011 Is quality of life impairment in asthma comparable to chronic urticaria? Source: Eur Respir J 2007; 30: Suppl. 51, 627s Year: 2007 Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017